Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) Equity Average (2019 - 2025)

Pulmonx (LUNG) has disclosed Equity Average for 7 consecutive years, with $73.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Equity Average fell 30.67% to $73.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $73.4 million, a 30.67% decrease, with the full-year FY2024 number at $102.1 million, down 25.04% from a year prior.
  • Equity Average was $73.4 million for Q2 2025 at Pulmonx, down from $81.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $221.1 million in Q1 2021 to a low of $73.4 million in Q2 2025.
  • A 5-year average of $148.7 million and a median of $153.9 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 215.96% in 2021, then tumbled 30.67% in 2025.
  • Pulmonx's Equity Average stood at $198.0 million in 2021, then decreased by 19.84% to $158.7 million in 2022, then dropped by 12.47% to $138.9 million in 2023, then plummeted by 35.32% to $89.9 million in 2024, then dropped by 18.35% to $73.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Equity Average are $73.4 million (Q2 2025), $81.7 million (Q1 2025), and $89.9 million (Q4 2024).